Histogen and WealthForge Launch New Financing Partnership

NEW YORK,  -WealthForge, a provider of turnkey technology solutions for processing private placement securities offerings, today announced they will serve as lead placement agent in a collaboration with Gar Wood Securities on Histogen Inc.’s $18M Series D round of financing.

Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen’s technology focuses on stimulating a patient’s own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation.

In May 2015, Histogen opened its Series D financing round to support clinical development of its Hair Stimulating Complex (HSC), including a US Phase I clinical trial in female diffuse hair loss patients and a late-stage HSC trial in male pattern hair loss, expand its manufacturing capability, and to support preparation for an initial public offering (IPO).

“Histogen is pleased to partner with WealthForge on this financing raise,” said Dr. Gail K. Naughton, CEO and Chairman of the Board of Histogen. “WealthForge’s platform and services will not only ensure our SEC compliance for these transactions, but will facilitate the investment process for our new shareholders.”

WealthForge helps firms raising private capital utilizing cutting-edge technology that enables the compliant processing of private placements. Their solution takes a traditionally cumbersome, risk-laden and manual transaction and transforms it into a faster, easier and more compliant process.

“At WealthForge, our mission is simple – to lower costs throughout the entire private placement process.” Arthur Weissman, Head of Sales and Marketing said. “We’re proud to work with a partner like Histogen to help them scale their business by making the process of raising private capital faster and more compliant than ever before.”

In an effort to support Histogen, WealthForge is working closely with Gar Wood Securities, an experienced broker-dealer in the industry.

“We are very excited about the development in stem cell research and are thrilled to be working with Dr. Gail K. Naughton, as she and her team prepare for their next phase of testing,” said Robert Jersey, President and CEO of Gar Wood Securities, LLC.

About Gar Wood Securities, LLC

Gar Wood Securities, LLC is a boutique, institutional broker-dealer that is known for its derivative execution and prime brokerage businesses.  The firm supports a network of independent contractors that trade solely on an agency basis, and who have access to all major global markets covering equities and cash options.

The firm is a registered Broker Dealer and member of FINRA, NFA, and SIPC.

For additional information about Gar Wood Securities, LLC please visit www.garwoodsecurities.net.

For more information about Histogen, its technology and products, please visit www.histogen.com.

For more information about how WealthForge can help simplify the process of raising private capital, please visit www.wealthforge.com.

Originally published at PRNewswire.